Zobrazeno 1 - 10
of 809
pro vyhledávání: '"G. Stoter"'
Autor:
Marjolein Bannink, Simon Scharpé, A. M. M. Eggermont, G. Stoter, Wim H. J. Kruit, Durk Fekkes, Robert Verkerk, B. van der Holt, A. R. Van Gool, Michiel W. Hengeveld, Stefan Sleijfer
Publikováno v:
Journal of Interferon and Cytokine Research, 28(5), 283-286. Mary Ann Liebert Inc.
Journal of interferon and cytokine research
Journal of interferon and cytokine research
Abnormal activity in peripheral blood of the cytosolic enzyme prolyl endopeptidase (PEP, EC 3.4.21.26, post prolyl cleaving enzyme, prolyl oligopeptidase) has been found in patients with a variety of psychiatric disorders, most consistently in mood d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::786d8f5d452187e878dc832e8684c9a1
https://hdl.handle.net/1765/32281
https://hdl.handle.net/1765/32281
Autor:
M.E.L. van der Burg, Jozien Helleman, D. Van Der Vlies, Machiel H. Jansen, T. M. Luider, Emjj Berns, G. Stoter
Publikováno v:
International Journal of Gynecological Cancer, 18(5), 985-995. BMJ Publishing Group
We set out to discover ovarian cancer biomarkers useful for monitoring progression during and after chemotherapy and possibly for diagnosis. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry was used to create serum protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d3b196d6a42a051d61c1c1b514d53b
https://doi.org/10.1111/j.1525-1438.2007.01139.x
https://doi.org/10.1111/j.1525-1438.2007.01139.x
Publikováno v:
Journal of Organometallic Chemistry. 691:2554-2562
Multinuclear NMR ( 1 H, 13 C and 119 Sn), FT-IR, 119m Sn Mossbauer spectroscopy, elemental analysis and MS have been carried out for five newly synthesized triorganotin(IV) esters of N -maleoyl-protected tranexamic acid. As per spectroscopic outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6a92aeab3da52e52c9f14e581dbaae5
https://doi.org/10.1016/j.jorganchem.2006.01.057
https://doi.org/10.1016/j.jorganchem.2006.01.057
Publikováno v:
Pharmacy World & Science, 27(6), 423-431. Springer Netherlands
Interferon-alpha (IFN-alpha) has been extensively explored for its efficacy in various disease conditions and is currently used as a standard treatment in several of these. Its use is accompanied by a wide variety of possible side effects. These side
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a253d29220044c8e34bda23fd601faf
https://hdl.handle.net/1765/63980
https://hdl.handle.net/1765/63980
Publikováno v:
European Journal of Cancer, 40, 2377-2382. Elsevier Ltd.
Following reports of its teratogenicity, thalidomide was banned from the market in the 1960s. Later, the elucidation that the inhibition of angiogenesis underlies this teratogenicity and the recognition of the importance of angiogenesis in malignanci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4aefcd3b27ff369fa7a1654da2025a
https://doi.org/10.1016/j.ejca.2004.07.023
https://doi.org/10.1016/j.ejca.2004.07.023
Autor:
Simon Scharpé, Wim H. J. Kruit, A. R. Van Gool, Durk Fekkes, G. Stoter, Marjolein Bannink, Michael Maes, A. M. M. Eggermont, H.H. van Ojik, Paul G.H. Mulder, Robert Verkerk
Publikováno v:
Journal of Interferon and Cytokine Research, 24, 411-415. Mary Ann Liebert Inc.
Journal of interferon and cytokine research
Journal of interferon and cytokine research
Immunotherapy with interferon-alpha (IFN-alpha) induces neuropsychiatric side effects, most notably depression. In hepatitis patients treated with IFN-alpha, severity of depression correlates with a decrease in serum activity of dipeptidyl peptidase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1326cb6caadc455497f3dc9e89b785ef
https://doi.org/10.1089/1079990041535629
https://doi.org/10.1089/1079990041535629
Autor:
R. Hoekstra, A. van der Gaast, G. Stoter, M. B. Polee, Peter D. Siersema, M.E.L. van der Burg, Ferry A.L.M. Eskens, H. W. Tilanus
Publikováno v:
Annals of Oncology, 14, 1253-1257. Elsevier Ltd.
We have previously reported a favourable response rate in patients with advanced esophageal cancer after treatment with a biweekly regimen of paclitaxel and cisplatin. In this study we investigate the feasibility and efficacy of this regimen in a neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb3534823b84b0f6cd907c1e0dc2a53
https://doi.org/10.1093/annonc/mdg328
https://doi.org/10.1093/annonc/mdg328
Autor:
M.E.L. van der Burg, Jaap Verweij, S J Veltman, F.E. de Jongh, R. de Wit, Wilfried J. Graveland, G Stoter, R N van Veen, M. J. van den Bent, A. S. T. Planting
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 88, 1199-1206. Nature Publishing Group
British Journal of Cancer, 88, 1199-1206. Nature Publishing Group
In the present study we describe the toxicity of weekly high-dose (70-85 mg x m(-2)) cisplatin in 400 patients (203 men, 197 women; median age 54 years) with advanced solid tumours treated in the period 1990-2001 who took part in phase I/II trials, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51673a900f37c59e58756c0ade2c501e
http://europepmc.org/articles/PMC2747572
http://europepmc.org/articles/PMC2747572
Autor:
Marjolein Bannink, Wim H. J. Kruit, Arthur R. Van Gool, G. Stoter, Frederike K. Engels, Alexander M.M. Eggermont
Publikováno v:
Pharmacy World and Science. 25:11-20
Aim: Immunotherapy with interferon‐alfa (IFN‐alfa) is used in a variety of diseases in‐ and outside clinical trials (e.g. chronic hepatitis, melanoma, chronic myelogenous leukemia, renal cell carcinoma, multiple myeloma). Treatment with IFN‐a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7748108f2bd448d2b4c3e2c6b53ffad
https://doi.org/10.1023/a:1022449613907
https://doi.org/10.1023/a:1022449613907
Autor:
G. Stoter, M.E.L. van der Burg, Jaap Verweij, M. J. van den Bent, R. de Wit, Alex Sparreboom, F.E. de Jongh
Publikováno v:
European Journal of Cancer. 38:2005-2013
A randomised phase I/II trial with weekly cisplatin 70 mg/m2 (days 1, 8, 15, 29, 36, 43) in combination with escalating doses of paclitaxel either 4-weekly or weekly was conducted in 49 patients with ovarian cancer; patients were chemotherapy-naive o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c66e6220dc807764b8ee9ecc40a8413
https://doi.org/10.1016/s0959-8049(02)00242-3
https://doi.org/10.1016/s0959-8049(02)00242-3